Journal
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Volume 80, Issue 4, Pages 1013-1021Publisher
MOSBY-ELSEVIER
DOI: 10.1016/j.jaad.2018.11.059
Keywords
biologics; biomarkers; EASI; IGA; pruritus; T(H)2; topical corticosteroids
Categories
Funding
- MedImmune, a AstraZeneca Group
- Amgen
Ask authors/readers for more resources
Background: Tezepelumab (AMG 157/MEDI9929), a first-in-class monoclonal antibody, targets thymic stromal lymphopoietin, a cytokine that is implicated in the pathogenesis of atopic dermatitis (AD). Objective: We sought to evaluate the efficacy and safety of tezepelumab in adults with moderate to severe AD. Methods: In this phase 2a study (NCT02525094), 113 patients were randomized 1: 1 to subcutaneous tezepelumab 280 mg or placebo every 2 weeks, plus class 3 topical corticosteroids (TCS). The primary endpoint was the week 12 response rate for a >= 50% reduction in the Eczema Area and Severity Index (EASI50). Secondary endpoints including EASI75, Investigator's Global Assessment, SCORAD 50, SCORAD 75, pruritus numeric rating and 5-D itch scales, and exploratory endpoints (including EASI90) were assessed at weeks 12, and 16 (post hoc). Results: A numerically greater percentage of tezepelumab plus TCS-treated patients achieved EASI50 (64.7%) versus placebo plus TCS (48.2%; P = .091). Numerical improvements over placebo were demonstrated for week 12 secondary and exploratory endpoints, with further improvements at week 16. Treatment-emergent adverse events were similar between treatment groups. Limitations: Greater than expected response rates in placebo-treated patients were possibly attributable to TCS. Conclusion: Although not statistically significant, numerical improvements over placebo for all week 12 endpoints were demonstrated, with greater week 16 responses.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available